Acute Pericarditis: Diagnosis and Treatment
For acute pericarditis, start aspirin or ibuprofen with colchicine immediately—this combination is Class I, Level A evidence and reduces recurrence from 37.5% to 16.7% 1.
Diagnostic Approach
Diagnose acute pericarditis when at least 2 of the following 4 criteria are present 1, 2:
- Pleuritic chest pain (sharp, worse when supine, relieved by sitting forward) - present in ~90% of cases
- Pericardial friction rub - present in <30% of cases
- New widespread ST-elevation and PR depression on ECG - present in 25-50% of cases
- New or worsening pericardial effusion on echocardiography - present in ~60%, usually small
Essential Initial Workup
Obtain these tests on all suspected cases 1:
- Physical examination (listen for friction rub)
- ECG (look for diffuse ST elevation, PR depression)
- Chest X-ray
- Echocardiogram (assess for effusion, tamponade)
- C-reactive protein (CRP) - critical for guiding treatment duration
- Troponin (elevated in myopericarditis)
Risk Stratification
High-risk features requiring admission and etiologic workup 1:
- Fever >38°C
- Subacute onset (symptoms developing over days-weeks)
- Large pericardial effusion (>20mm)
- Cardiac tamponade
- Failure to respond to NSAIDs after 7 days
- Myopericarditis (elevated troponin)
- Immunosuppression
- Trauma
- Oral anticoagulation
Low-risk patients without these features can be managed as outpatients 1.
First-Line Treatment
The Winning Combination: NSAIDs + Colchicine
Aspirin or Ibuprofen (choose one) 1:
- Aspirin: 750-1000 mg every 8 hours
- Ibuprofen: 600 mg every 8 hours
- Duration: 1-2 weeks typically, guided by symptoms and CRP normalization
- Always provide gastroprotection (PPI)
- Taper gradually: decrease aspirin by 250-500 mg every 1-2 weeks; ibuprofen by 200-400 mg every 1-2 weeks
PLUS Colchicine (mandatory, not optional) 1:
- <70 kg: 0.5 mg once daily
- ≥70 kg: 0.5 mg twice daily
- Duration: 3 months for first episode
- Tapering not mandatory but can use 0.5 mg every other day in final weeks
- This reduces recurrence risk by approximately 50% 1, 2
Critical Pitfall: Avoid Corticosteroids as First-Line
Corticosteroids are NOT recommended for initial therapy (Class III recommendation) 1. They promote chronicity, drug dependence, and increase recurrence rates to 50% 1. The guidelines are emphatic about this.
When to Use Corticosteroids
Reserve low-dose corticosteroids (prednisone 0.2-0.5 mg/kg/day) ONLY for 1:
- Contraindication to both aspirin/NSAIDs AND colchicine
- Failure of aspirin/NSAIDs and colchicine after adequate trial
- Specific indications: autoimmune disease, post-pericardiotomy syndrome, pregnancy
- Must exclude infectious causes first, especially tuberculosis
Maintain initial dose until symptom resolution and CRP normalization, then taper slowly 1.
Activity Restriction
Non-athletes 1:
- Restrict physical activity beyond ordinary sedentary life until symptoms resolve AND CRP, ECG, and echocardiogram normalize
Athletes 1:
- Minimum 3 months restriction from competitive sports after symptom onset
- Can return only after complete resolution of symptoms AND normalization of CRP, ECG, and echocardiogram
Monitoring Treatment Response
Use CRP to guide therapy 1:
- Check CRP at baseline and during follow-up
- Continue treatment until CRP normalizes
- Persistent elevation suggests inadequate treatment or alternative diagnosis
- CRP normalization typically occurs over 1-2 weeks in uncomplicated cases
Recurrent Pericarditis
If pericarditis recurs (15-30% risk without colchicine) 1:
- Extend colchicine to at least 6 months 1, 2
- Continue aspirin/NSAIDs as needed
- If multiple recurrences despite optimal therapy, consider IL-1 inhibitors (anakinra or rilonacept) before escalating corticosteroids 3, 2
Key Point on Recurrence
A common cause of recurrence is inadequate treatment of the first episode 1. This underscores the importance of completing the full 3-month colchicine course and ensuring CRP normalization before tapering NSAIDs.
Prognosis
Most patients with idiopathic/viral pericarditis have excellent long-term outcomes 1: